NASDAQ:EIGR

Eiger BioPharmaceuticals, Inc Earning Date

USA |NASDAQ |USD

EIGR Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Nov 3, 2021 Sep 2021 $-0.56 $-0.57 $-0.52
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Nov 3, 2021 Sep 2021 $2.88M $2.10M $0.00

Eiger Biopharmaceuticals, Inc's next earnings date is Wednesday, Nov 3, 2021 for the fiscal quarter ending Sep 2021.

EIGR Earnings Date & History Chart

EIGR Earnings & Revenue Forecast

EIGR Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 5 $-0.55 $-0.59 $-0.52
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 4 $-0.81 $-0.85 $-0.76
Dec 2022 5 $-1.81 $-2.22 $-0.99

EIGR Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2021 0 / 0 $-0.54 $-0.54 $-0.59
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2021 0 / 0 $-0.79 $-0.79 $-0.87
Dec 2022 0 / 0 $-1.80 $-1.80 $-1.75

EIGR Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Dec 2021 4 $3.69M $2.73M $5.30M
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 5 $12.64M $10.42M $15.10M
Dec 2022 5 $34.57M $12.29M $71.00M

EIGR Earnings Date & Revenue History

EIGR Earnings History

|
Show More
Show More

EIGR Revenue History

|
Show More
Show More

Eiger Biopharmaceuticals, Inc Next Earnings Date & Report

EIGR Next Earnings Date & Report Preview: Sep 2021 (FQ)

EIGR's next earnings date is Wednesday, Nov 3, 2021 for the fiscal quarter ending Sep 30, 2021.

According to 5 analysts, the average EPS estimation for Eiger Biopharmaceuticals, Inc's next quarterly earnings is $-0.56, with a low EPS estimation of $-0.58, and a high estimation of $-0.54.

Over the last 1 month, EPS estimates have seen 0 upward revisions and 0 downward. The EPS 1 month trend is $-0.55, the last 2 month trend is $-0.55, and the 3 month trend is $-0.56.

Based on 5 analysts, the average revenue estimation is $2.88M, with a low revenue estimation of $2.03M, and a high estimation of $4.00M.

Eiger Biopharmaceuticals, Inc Previous Earnings Dates & Reports

EIGR Previous Earnings Date & Report Recap: Jun 2021 (FQ)

Eiger Biopharmaceuticals, Inc's previous earnings date was Aug 5, 2021 for its fiscal quarter ended Jun 30, 2021.

EIGR's earnings per share (EPS) was $-0.57, missing the consensus analysts forecast of $-0.56 by -2.43%.

The EPS was lower than the previous fiscal quarter (Mar 2021) by -167.06%, and higher than the same period a year before (Jun 2020) by -5.00%.

Revenues were $2.10M.

The company reported a net income of $-19.17M.

Free cash flow for the quarter was $-20.46M , compared to $-63.46M last quarter and $-15.90M a year before.

EIGR ended the quarter with $32.43M in total debt, an increase of 1.92% compared to the previous quarter, and an increase of 5.36% compared to the same quarter a year before.

EIGR Previous Earnings Date & Report Recap: Dec 2020 (FY)

Eiger Biopharmaceuticals, Inc's previous annual earnings date was Mar 9, 2021 for its fiscal year ended Dec 31, 2020.

EIGR's earnings per share (EPS) was $-2.31, missing the consensus analysts forecast of $-1.38 by 67.39% , and higher than the previous year's EPS (Dec 2019) by -25.48%.

Revenues were $0.00.

The company reported a net income of $-65.05M.

Eiger Biopharmaceuticals, Inc reported a free cash flow of $-63.44M for its fiscal year, compared to $-64.09M a year ago.

The company ended the fiscal year with $31.78M in total debt, an increase of 2.76% compared to the previous year.